National Agri-Marketing Association
NAMA Website
Upcoming Events
Agri-Marketing Conf
Best of NAMA 2017
Member Directory

Source: Boehringer Ingelheim news release

To view the complete report, click here.

The research-driven pharmaceutical company Boehringer Ingelheim is pleased with the 2013 financial year. Despite some challenges, the company succeeded in increasing its operating income and the return on net sales.

Boehringer Ingelheim generated net sales of around €14.1 billion, which represents an increase of 1.4 per cent, currency-adjusted (-4.3 per cent in euro terms). This resulted in a 2.4 percentage point improvement in the return on net sales to 15 per cent.

For the current financial year, the company expects net sales to remain at a comparable level to that of 2013. Boehringer Ingelheim now employs more than 47,400 people worldwide, which is three per cent more than in the previous year.

"2013 was for Boehringer Ingelheim a year marked by many successes and some challenges," said Professor Andreas Barner, Chairman of the Board of Managing Directors of Boehringer Ingelheim, at today's Annual Press Conference in Ingelheim. "We concentrated on continuing our work on the long-term development of the company."

With afatinib, for the targeted treatment of a specific form of lung cancer, Boehringer Ingelheim last year successfully entered the oncology market.

The compound was launched in the USA under the brand name of GlLOTRIF® and the launch has in the meantime started in the European Union under the name of GIOTRIF®. A second new product launch in 2013 was STRIVERDI® RESPIMAT® (olodaterol) for chronic obstructive pulmonary disease (COPD).

In its Animal Health business, Boehringer Ingelheim in 2013 exceeded the €1 billion mark in net sales. This represents an increase of 4.5 per cent, currency-adjusted (+0.8 per cent in euro terms), and eight per cent of total net sales.

The best-selling product, with net sales of €260 million, was the swine vaccine INGELVAC CIRCOFLEX®, as in the previous year. With an increase of 20.9 per cent, currency-adjusted (+16.2 per cent in euro terms), INGELVAC® PRRS, for the active immunisation of pigs against an infectious respiratory disease, achieved the greatest growth.

Search News & Articles

Proudly associated with:
American Business Media Canadian Agri-Marketing Association National Agri-Marketing Association
Agricultural Relations Council National Association of Farm Broadcasters American Agricultural Editors' Association Livestock Publications Council
All content © 2018, Henderson Communications LLC. | User Agreement